Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 I288_D304del |
Therapy | Infigratinib |
Indication/Tumor Type | cholangiocarcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 I288_D304del | cholangiocarcinoma | no benefit | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) did not decrease viability of a cholangiocarcinoma cell line expressing FGFR2 I288_D304del in culture (PMID: 37964396). | 37964396 |
PubMed Id | Reference Title | Details |
---|---|---|
(37964396) | Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas. | Full reference... |